Threshold Announces Initiation of Dosing With

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Threshold Announces Initiation of Dosing With TH-302/Bortezomib (Velcade(R))/Dexamethasone ("TBorD") in Final Stage of Ongoing Phase 1/2 Trial of Patients With Relapsed/Refractory Multiple Myeloma

SOUTH SAN FRANCISCO, CA--(Marketwired - Jul 9, 2014) - Threshold Pharmaceuticals, Inc. ( NASDAQ : THLD ) today announced that dosing has started in the final stage of an ongoing Phase 1/2 trial of its investigational hypoxia-activated prodrug, TH-302, in combination with the proteasome inhibitor bortezomib (Velcade ® ) and low-dose dexamethasone ("TBorD") in patients with relapsed/refractory multiple myeloma, a cancer of the bone marrow.

Initial results from the dose-escalation and dose-expansion stages of the trial evaluating TH-302 and low-dose dexamethasone without bortezomib were recently presented at the 50 th Annual Meeting of the American Society of Clinical Oncology (ASCO). As reported at ASCO, patients were heavily-pretreated (median 6.5 prior systemic therapies), and objective responses were observed in 5/16 (31%) patients (three partial responses and two minimal responses) treated at the maximum-tolerated dose of TH-302 (340 mg/m 2 ). 1

"Data seen thus far are encouraging using the combination of TH-302 and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma," said Irene Ghobrial, M.D., Medical Oncologist at Dana-Farber/Brigham and Women's Cancer Center and Principal Investigator of the Phase 1/2 trial. "I would like to acknowledge the Blood Cancer Research Partnership for their significant role in facilitating rapid accrual of patients to this study. We are excited to initiate this final stage in which patients will receive TH-302, bortezomib, and dexamethasone, particularly in light of preclinical research demonstrating synergistic cytotoxicity of TH-302 and bortezomib."

In the U.S. and Europe, there are an estimated 66,000 new cases of multiple myeloma per annum. 2,3 Current standards of care include alkylating agents, proteasome inhibitors, and immunomodulatory drugs (IMiDs). New treatment options for patients with advanced multiple myeloma who experience relapse of their disease or who become refractory to standard therapies remains an area of unmet medical need.

"The presence of hypoxia in the diseased bone marrow may present a new therapeutic target for treating multiple myeloma and underscores my enthusiasm for further evaluation of TH-302 in this disease," said Jacob Laubach, M.D., Clinical Director of the Jerome Lipper Multiple Myeloma Center at Dana-Farber/Brigham and Women's Cancer Center and a lead investigator on the Phase 1/2 trial.

The bone marrow in patients with multiple myeloma has been shown to be hypoxic, 4,5 and hypoxia has been implicated in the progression of multiple myeloma in vitro and in vivo . 6 TH-302 is a hypoxia-activated prodrug that is designed to selectively release bromo-isophosphoramide mustard (Br-IPM), a potent DNA-alkylating agent, under conditions of tumor hypoxia. TH-302 has demonstrated antimyeloma activity both in vitro and in vivo as well as synergistic cytotoxic activity with bortezomib in vitro . 7-9

About the Phase 1/2 Trial

The objectives of the ongoing Phase 1/2 trial combining TH-302 and dexamethasone with or without bortezomib include assessment of safety and tolerability, determination of dose-limiting toxicities and the maximum-tolerated dose of TH-302, and assessment of preliminary efficacy in patients with relapsed/refractory multiple myeloma.

The ASCO 2014 presentation included preliminary data from 24 patients in the dose-escalation and dose-expansion portions of the study who initiated treatment with TH-302 and low-dose dexamethasone prior to March 1, 2014; analyses reflected the clinical database as of May 19, 2014. Of these 24 patients, 17 were treated at the maximum tolerated dose of TH-302 (340 mg/m 2 ).

In these patients, the most common adverse events related to TH-302 were nausea and fatigue that occurred in at least 25% of the patients. The most common Grade 3/4 hematologic adverse events related to TH-302 were thrombocytopenia (29%) and leukopenia (25%). Dose-limiting toxicities of Grade 3 stomatitis were reported during the first treatment cycle for the first two patients treated at 480 mg/m 2 TH-302; therefore, the maximum tolerated dose of TH-302 in combination with low-dose dexamethasone was established at 340 mg/m 2 , as previously reported. 10

Of the 24 patients included in the ASCO presentation, 23 were evaluable for response. Best responses included four partial responses (4 PR), two minimal responses (2 MR), and 15 stable disease (15 SD) assessments; two patients had progressive disease (2 PD). The clinical benefit rate for patients treated at the maximum tolerated dose of TH-302 (340 mg/m 2 , n=16 evaluable patients) was 31% (comprised of 3 PR and 2 MR).

In the final stage of the trial to evaluate T H-302, bor tezomib, and low-dose d examethasone ("TBorD"), an initial dose of TH-302 of 240 mg/m 2 will be administered twice weekly for the first two weeks of a three-week treatment cycle. The dose of TH-302 will be escalated in cohorts of 3-6 patients. The dose of bortezomib will remain fixed at 1.3 mg/m 2 .

About TH-302

TH-302 is an investigational hypoxia-activated prodrug that is designed to be activated under tumor hypoxic conditions, a hallmark of many cancers. Areas of low oxygen levels (hypoxia) in solid tumors are due to insufficient blood supply as a result of aberrant vasculature. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be severely hypoxic.

TH-302 is currently under evaluation in two Phase 3 trials: one in combination with doxorubicin versus doxorubicin alone in patients with soft tissue sarcoma, and the other in combination with gemcitabine versus gemcitabine and placebo in patients with advanced pancreatic cancer (the "MAESTRO" trial). Both Phase 3 trials are being conducted under Special Protocol Agreements with the U.S. Food and Drug Administration (FDA). The FDA and the European Commission have granted TH-302 Orphan Drug Designation for the treatment of soft tissue sarcoma and pancreatic cancer. TH-302 is also being investigated in earlier-stage clinical trials of other solid tumors and hematological malignancies, in combination with chemotherapy and antiangiogenic therapy, and for certain cancers, is being investigated as a monotherapy.

Threshold has a global license and co-development agreement for TH-302 with Merck KGaA, Darmstadt, Germany, which includes an option for Threshold to co-commercialize in the U.S.

About the Blood Cancer Research Partnership

The Leukemia & Lymphoma Society and Dana-Farber Cancer Institute have established a network of sites for clinical trial testing of innovative blood cancer therapies in community oncology settings across the country. This groundbreaking Blood Cancer Research Partnership (BCRP) brings clinical trials closer to where patients live and helps to address one of the primary bottlenecks in the development of new cancer therapies: the need for more patients to take part in trials.

About Threshold Pharmaceuticals

Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ( www.thresholdpharm.com ).

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the potential therapeutic uses and benefits of TH-302, including TH-302's potential to be a component of new combination approaches to treating multiple myeloma. Potential risks and uncertainties include, but are not limited to: the ability of Threshold and Merck KGaA, Darmstadt, Germany, to enroll or complete TH-302 clinical trials; the time and expense required to conduct such clinical trials and analyze data; issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results); the risk that preclinical studies in animal models of disease may not accurately predict the results of human clinical trials of TH-302; the risk that the final data from ongoing trials may be materially different from the preliminary data that Threshold has reported; Threshold's and Merck KGaA's (Darmstadt, Germany) dependence on single source suppliers, including the risk that these single source suppliers may be unable to meet clinical supply demands for TH-302 which could significantly delay the development of TH-302; risks related to Threshold's dependence on its collaborative relationship with Merck KGaA, Darmstadt, Germany, including its dependence on decisions by Merck KGaA, Darmstadt, Germany regarding the amount and timing of resource expenditures for the development of TH-302; and Threshold's need for and the availability of resources to develop TH-302 and to support Threshold's operations. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on May 1, 2014 and is available from the SEC's website ( www.sec.gov ) and on our website ( www.thresholdpharm.com ) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.

References

1. Laubach J, et al. Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM). Journal of Clinical Oncology 32: 8534, 2014. 2. American Cancer Society. Cancer Facts and Figures 2014. http://www.cancer.org/acs/groups/content/@res...042151.pdf (accessed July 3, 2014). 3. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. http://globocan.iarc.fr/Pages/online.aspx (accessed July 3, 2014). 4. Colla S, et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 24: 1967-1970, 2010. 5. Martin SK, et al. Hypoxia-inducible factor-2 is a novel regulator of aberrant CXCL12 expression in multiple myeloma plasma cells. Haematologica 95: 776-784, 2010. 6. Azab AK, et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 119: 5782-5794, 2012. 7. Hu J, et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 116: 1524-1527, 2010. 8. Chesi M, et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy.  Blood 120: 376-385, 2012. 9. Hu J, et al. Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro . Mol Cancer Ther 12: 1763-1773, 2013. 10. Ghobrial IM, et al. Phase 1 study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood 122: 1948, 2013.

Contact Laura Hansen, Ph.D. Senior Director, Corporate Communications Phone: 650-703-6523 E-mail: lhansen@thresholdpharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

UAE Trust Model Faces Its Hardest Test During Crisis

Updated Category News Views 205

A country’s reputation is usually invisible right up until the machinery rattles. Then people, investors, trading partners and residents stop listening to polished slogans and start watching whether airports function, services hold up, information arrives, and business can keep moving. That was the useful core of Saeed Al Eter’s remarks at Ajman Media Forum 2026: soft...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 404

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 405

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 411

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 299

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
D-Wave Investors Face a December 15 Lead Plaintiff Clock

Updated Category News Views 286

August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 330

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 196

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading
Human Frontier Mission Puts AI Research on Display

Updated Category News Views 221

A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...

Continue Reading
Employer Ghosting Is a Quiet Talent-Cost Problem Today

Updated Category News Views 327

Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...

Continue Reading

Top 5 Most Recently Viewed Articles

CorMedix Achieves 52-Week High Amidst Business Expansion Strategies

Updated Category News Views 122

CorMedix Stock Reaches New Heights CorMedix Inc. has recently celebrated a milestone by reaching a new 52-week high, with shares hitting $10.15. This significant achievement comes as part of a broader trend of notable expansion and investor confidence in the pharmaceutical and medical device sector. Over the past year, CorMedix's stock has increased by an impressive...

Continue Reading
Norway's Wealth Fund Shifts Ethics Standards Amid Gaza Conflict

Updated Category News Views 148

Norway's Wealth Fund Takes a Stand on Ethical Investments Norway's $1.7 trillion wealth fund is currently navigating a challenging ethical landscape as it considers pulling investments from companies associated with operations in the occupied Palestinian territories. The fund's Council on Ethics has adopted a stricter interpretation of its ethical standards, which could...

Continue Reading
Bonduelle's Monthly Share and Voting Rights Update

Updated Category News Views 120

Overview of Bonduelle's Monthly Share and Voting Rights Update Bonduelle, a prominent player in the food industry, is well-known for its commitment to providing high-quality vegetable products. Headquartered in an innovative facility, their corporate structure includes a significant capital invested which showcases their strong market presence. Latest Information on...

Continue Reading
Innovative Partnership Launches Unique Aging and Cancer Research Institute

Updated Category News Views 193

Innovative Partnership in Cancer Research The Mark Foundation for Cancer Research (MFCR) and the Samuel Waxman Cancer Research Foundation (SWCRF) have entered a groundbreaking collaboration to create the Samuel Waxman Institute for Aging & Cancer. This institute will serve as the first dedicated global center exploring how aging impacts cancer risk throughout a person's...

Continue Reading
Market Overview: Nasdaq Surges as Stocks Show Mixed Trends

Updated Category News Views 201

Market Overview: Nasdaq Shows Strength The U.S. stock markets experienced a mixed performance recently, with the Nasdaq Composite recording a notable gain of over 50 points. This uptick brings attention to sector volatility and specific stock behaviors that investors should closely monitor. Daily Market Trends After the markets opened, the Dow Jones Industrial Average saw...

Continue Reading